Acadian Asset Management LLC Cellectis S.A. Transaction History

Acadian Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$11.94 - $16.09 $38,530 - $51,922	-3,227 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$14.36 - $20.93 $46,339 - $67,541	3,227 New	3,227 $50,000
Q1 2021 May 11, 2021	SELL	$18.19 - $33.25 $797,667 - $1.46 Million	-43,852 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$15.87 - $31.64 $361,058 - $719,841	-22,751 Reduced 34.16%	43,852 $1.19 Million
Q3 2020 Nov 09, 2020	SELL	$15.7 - $20.84 $65,233 - $86,590	-4,155 Reduced 5.87%	66,603 $1.23 Million
Q2 2020 Aug 12, 2020	BUY	$8.21 - $21.02 $580,923 - $1.49 Million	70,758 New	70,758 $1.26 Million

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.